We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer recently discussed.
Novartis AG (NYSE:NVS) is a Swiss pharmaceutical company that is one of the largest of its kind. Its shares have gained 17% year-to-date, but the shares lost 2.5% in July after the firm’s fiscal first quarter earnings report. The results saw Novartis AG (NYSE:NVS) post $14.05 billion in revenue, which fell short of analyst estimates of $14.18 billion. However, the firm’s operating profit sat at $5.93 billion which was higher than the $5.69 billion that analysts had penciled in. For his part, Cramer had a shocking question on his mind as he wondered whether Novartis AG (NYSE:NVS) CEO Dr. Vasant Narasimhan was leaving the company:
“[On NVS raising the guide and getting a buyback]”They did have one failure of a drug, that was very, very important but I saw that Vass, Vass is going? He’s a terrific CEO.”
Updated July 22nd, 2025: Novartis reached out to CNBC and confirmed that Cramer misspoke during the show. A Novartis spokesperson who reached out to Insider Monkey denied that the CEO was leaving and remarked: “Novartis CEO Vas Narasimhan is not leaving the company.”
A doctor holding a microscope in front of a laboratory sample of healthcare products.
Loomis Sayles Global Growth Fund mentioned Novartis AG (NYSE:NVS) in its Q1 2025 investor letter. Here is what the firm said:
“Novartis AG (NYSE:NVS) is a diversified global healthcare company with market leadership in branded pharmaceuticals across a broad range of treatment areas, including oncology (30% of revenues), immunology (almost 20% of revenues), cardiovascular, renal, and metabolic (almost 20%), and neurology (10%). The company also derives over 20% of revenues from mature branded products in non-core therapy areas. With the October 2023 spinoff of the company’s Sandoz generics and biosimilars division, which followed the 2019 spinoff of ophthalmologic equipment maker Alcon and 2018 divestiture of a consumer health joint venture, the company is now purely focused on innovative medicines, which accounted for about 80% of revenue and 85% of core operating income prior to the Sandoz spinoff. The company generates over 50% of revenue from the Americas, approximately 30% from Europe, and almost 20% from the rest of the world.”
While we acknowledge the risk and potential of NVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NVS and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center